SBILIFE vs SUNPHARMA: Stock Comparison
SUN PHARMACEUTICAL IND L is the larger company by market capitalisation. SUN PHARMACEUTICAL IND L shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
SBILIFE leads 0; SUNPHARMA leads 9 of 9
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | SBILIFE | SUNPHARMA |
|---|---|---|
| Sector | Financial Services | Healthcare |
| Industry | Life Insurance | Pharmaceuticals |
Price
| Metric | SBILIFE | SUNPHARMA |
|---|---|---|
| Live Price | ₹1,640 | ₹1,748 |
| Day Change | -0.18% | -0.57% |
| Volume | 9.8 L | 10.65 L |
| 52-Week High | ₹2,132 | ₹2,046.9 |
| 52-Week Low | ₹1,612.9 | ₹1,583.7 |
| Distance from 52W High | -23.08% | -14.6% |
Valuation
| Metric | SBILIFE | SUNPHARMA |
|---|---|---|
| Market Cap | ₹1.65 L Cr | ₹4.18 L Cr |
| P/E Ratio | 63.44x | 34.58x |
| P/B Ratio | 8.65x | 5x |
| EPS | ₹7.23 | ₹12.06 |
| Book Value | ₹190.24 | ₹349.6 |
| Dividend Yield | 0.16% | 0.92% |
Growth
| Metric | SBILIFE | SUNPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | -82.2% | 12.8% |
| EPS Growth (TTM YoY) | -1.1% | 25.6% |
| Qtr Sales Growth | — | 0% |
| Qtr Profit Growth | — | 0% |
Profitability & Leverage
Debt-to-equity is shown for reference only — it is not a like-for-like metric for banks and financials.| Metric | SBILIFE | SUNPHARMA |
|---|---|---|
| ROE | 12.94% | 13.72% |
| ROCE | — | 15.16% |
| Net Margin | 2.48% | 18.56% |
| Operating Margin | 2.25% | 26.44% |
| Debt to Equity | 0x | 0.05x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | SBILIFE | SUNPHARMA |
|---|---|---|
| Promoter Holding | 55.31%▼ 0.01 pp | 52.68%▼ 1.8 pp |
| FII Holding | 20.68%▼ 0.27 pp | 14.36%▼ 0.17 pp |
| DII Holding | 20.07%▲ 0.41 pp | 22.27%▲ 0.09 pp |
| Public Holding | 3.94%▼ 0.12 pp | 10.7%▲ 1.89 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SBI LIFE INSURANCE CO and SUN PHARMACEUTICAL IND L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.